Combination of Carmustine and Selenite Inhibits EGFR Mediated Growth Signaling in Androgen-Independent Prostate Cancer Cells

Journal of Cellular Biochemistry

Volumn 118, Issue 12, 2017, Pages 4331-4340

  Thamilselvan, Vijayalakshmi ^a   Menon, Mani ^a   Stein, Gary S ^b   Valeriote, Fred ^c   Thamilselvan, Sivagnanam ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

Akt; ANDROGEN INDEPENDENT PROSTATE CANCER; CARMUSTINE; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY; EGFR; ERK1 2; PC 3 CELLS; SELENITE

Indexed keywords

ANDROGEN RECEPTOR; CARMUSTINE; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SODIUM SELENITE; EGFR PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; SELENIOUS ACID;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; CELL PROLIFERATION; DRUG EFFECTS; MAPK SIGNALING; METABOLISM; MORTALITY; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

APOPTOSIS; CARMUSTINE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SELENIOUS ACID;

EID: 85031788655     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.26086     Document Type: Article

References (39)

1. Al Nakouzi N, Le Moulec S, Albiges L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y. 2015. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 68:228–235.
2. Bai D, Ueno L, Vogt PK. 2009. Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer 125:2863–2870.
3. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Jr., Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, Investigators C-A-. 2011. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005.
4. De Miguel P, Royuela, Bethencourt R, Ruiz A, Fraile B, Paniagua R. 1999. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. Cytokine 11:722–727.
5. Dhillon AS, Hagan S, Rath O, Kolch W. 2007. MAP kinase signalling pathways in cancer. Oncogene 26:3279–3290.
6. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F. 2002. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8:3438–3444.
7. Dreher T, Zentgraf H, Abel U, Kappeler A, Michel MS, Bleyl U, Grobholz R. 2004. Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch 444:509–517.
8. Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M. 2005. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Endocr Relat Cancer 12:983–998.
9. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr., Weber MJ. 1999. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59:279–284.
10. Godwin P, Baird AM, Heavey S, Barr MP, O'Byrne KJ, Gately K. 2013. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol 3:120.
11. Guo C, Luttrell LM, Price DT. 2000. Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines. J Urol 163:1027–1032.
12. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. 2009. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6:76–85.
13. Hour TC, Chung SD, Kang WY, Lin YC, Chuang SJ, Huang AM, Wu WJ, Huang SP, Huang CY, Pu YS. 2015. EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). Arch Toxicol 89:591–605.
14. Lamont KR, Tindall DJ. 2011. Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 25:897–907.
15. Lokeshwar VB, Lopez LE, Munoz D, Chi A, Shirodkar SP, Lokeshwar SD, Escudero DO, Dhir N, Altman N. 2010. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res 70:2613–2623.
16. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. 2007. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263–1284.
17. Mendelsohn J, Baselga J. 2000. The EGF receptor family as targets for cancer therapy. Oncogene 19:6550–6565.
18. Mimeault M, Batra SK. 2006. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 27:1–22.
19. Mimeault M, Johansson SL, Batra SK. 2012. Pathobiological implications of the expression of EGFR, pAkt, NF-kappaB and MIC-1 in prostate cancer stem cells and their progenies. PLoS ONE 7:e31919.
20. Mimeault M, Johansson SL, Vankatraman G, Moore E, Henichart JP, Depreux P, Lin MF, Batra SK. 2007. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther 6:967–978.
21. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, Plaisier S, Garraway IP, Huang J, Graeber TG, Wu H. 2011. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19:792–804.
22. Murillo H, Schmidt LJ, Tindall DJ. 2001. Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2. Cancer Res 61:7408–7412.
23. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. 1999. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401:82–85.
24. Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H. 2004. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate 58:259–268.
25. Price DT, Della Rocca G, Guo C, Ballo MS, Schwinn DA, Luttrell LM. 1999. Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 162:1537–1542.
26. Reuter S, Eifes S, Dicato M, Aggarwal BB, Diederich M. 2008. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 76:1340–1351.
27. Rodriguez-Berriguete G, Fraile B, Martinez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M. 2012. MAP kinases and prostate cancer. J Signal Transduct 2012:169170.
28. Sato K. 2013. Cellular functions regulated by phosphorylation of EGFR on Tyr845. Int J Mol Sci 14:10761–10790.
29. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, Investigators A. 2012. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197.
30. Sharma SV, Bell DW, Settleman J, Haber DA. 2007. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169–181.
31. Shiota M, Bishop JL, Takeuchi A, Nip KM, Cordonnier T, Beraldi E, Kuruma H, Gleave ME, Zoubeidi A. 2015. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer. Oncotarget 6:9086–9098.
32. Thamilselvan V, Menon M, Thamilselvan S. 2011. Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 beta/beta-catenin pathway. Int J Cancer 129:2916–2927.
33. Thamilselvan V, Menon M, Thamilselvan S. 2012. Carmustine enhances the anticancer activity of selenite in androgen-independent prostate cancer cells. Cancer Manag Res 4:383–395.
34. Thamilselvan V, Menon M, Thamilselvan S. 2016. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer. Int J Cancer 139:1632–1647.
35. Thanos D, Maniatis T. 1995. NF-kappa B: A lesson in family values. Cell 80:529–532.
36. Traish AM, Morgentaler A. 2009. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer 101:1949–1956.
37. Yamamoto T, Ebisuya M, Ashida F, Okamoto K, Yonehara S, Nishida E. 2006. Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. Curr Biol 16:1171–1182.
38. Yang J, Amiri KI, Burke JR, Schmid JA, Richmond A. 2006. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: Involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res 12:950–960.
39. Zollo M, Di Dato V, Spano D, De Martino D, Liguori L, Marino N, Vastolo V, Navas L, Garrone B, Mangano G, Biondi G, Guglielmotti A. 2012. Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin Exp Metastasis 29:585–601.